Pharmaceutical firm expands capabilities with £45m acquisition
Pharmaceutical firm, Recipharm, has announced a £45m acquisition of French multinational pharmaceutical company Sanofi.
The firm has said that the acquired business will enhance the group’s scale and provide access to new customers and higher margin specialised technologies.
The acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel provides Recipharm with a solid platform to take further advantage of the growing respiratory drug market, the group said.
It also adds additional inhalation commercial drug product manufacturing capabilities, complementing services already offered by the group’s inhalation development facility in the US.
Thomas Eldered, CEO of Recipharm, said: “Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel of respiratory products.
“As an already successful CMO with several clients, we look forward to introducing new contracts to Holmes Chapel by utilising our growing franchise in development services. Treatments for asthma and chronic obstructive pulmonary disease (COPD) are growing at a fast rate and we see many opportunities.
“The experienced management team and staff have already successfully attracted new customers and we look forward to building on this from the well invested facility.”